Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Jazz Pharma Plc (JAZZ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 10,594,101
  • Shares Outstanding, K 60,410
  • Annual Sales, $ 1,619 M
  • Annual Income, $ 487,850 K
  • 36-Month Beta 0.90
  • Price/Sales 6.57
  • Price/Cash Flow 13.52
  • Price/Book 3.70

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 3.00
  • Number of Estimates 3
  • High Estimate 3.07
  • Low Estimate 2.91
  • Prior Year 2.93
  • Growth Rate Est. (year over year) +2.39%

Price Performance

See More
Period Period Low Period High Performance
1-Month
170.00 +3.92%
on 08/02/18
181.46 -2.64%
on 08/07/18
+0.69 (+0.39%)
since 07/13/18
3-Month
159.89 +10.49%
on 05/16/18
184.00 -3.98%
on 06/20/18
+10.67 (+6.43%)
since 05/14/18
52-Week
128.58 +37.40%
on 11/07/17
184.00 -3.98%
on 06/20/18
+32.70 (+22.71%)
since 08/14/17

Most Recent Stories

More News
Jazz Pharma's (JAZZ) Stock Down Despite Q2 Earnings Beat

Jazz Pharmaceuticals (JAZZ) beats estimates for both earnings and sales in Q2. However, sales of its newest drug, Vyxeos disappoint. Stock down 7% in after-hours trading.

JAZZ : 176.31 (+0.54%)
AERI : 64.75 (+0.94%)
VRTX : 176.52 (+0.84%)
SGEN : 74.25 (+0.61%)
Jazz Pharmaceuticals Announces Second Quarter 2018 Financial Results

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the second quarter of 2018 and updated financial guidance for 2018.

JAZZ : 176.31 (+0.54%)
Jazz Pharmaceuticals Plc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Jazz Pharmaceuticals Plc (NASDAQ: ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time....

JAZZ : 176.31 (+0.54%)
Jazz Pharmaceuticals and MD Anderson Cancer Center Collaborate to Evaluate Potential Treatment Options for Hematologic Malignancies

DUBLIN and HOUSTON, Aug. 6, 2018 /PRNewswire/ -- Jazz Pharmaceuticals plc and The University of Texas MD Anderson Cancer Center today announced a five-year collaboration agreement with a goal of evaluating...

JAZZ : 176.31 (+0.54%)
Jazz Pharma (JAZZ) Q2 Earnings Coming Up: What's in Store?

Jazz's (JAZZ) Xyrem will likely continue to do well in the second quarter. Supply constraints will continue to hurt sales of Erwinaze.

SRPT : 125.86 (-1.05%)
JAZZ : 176.31 (+0.54%)
BDSI : 2.67 (+0.75%)
MDGL : 230.95 (+2.01%)
Why Earnings Season Could Be Great for Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals (JAZZ) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.

JAZZ : 176.31 (+0.54%)
Will Wdesk Cloud Platform Drive Workiva's (WK) Q2 Earnings?

Workiva (WK) continues to focus on developing its flagship product, Wdesk cloud platform, which continues to gain traction.

SAP : 113.54 (-0.49%)
WK : 30.50 (+0.83%)
JAZZ : 176.31 (+0.54%)
PPL : 29.12 (+0.17%)
CMS Grants New Technology Add-On Payment to Vyxeos® (daunorubicin and cytarabine) Liposome for Injection

Jazz Pharmaceuticals plc today announced that the United States Centers for Medicare and Medicaid Services (CMS) granted approval for a New Technology Add-on Payment (NTAP) for Vyxeos(R) (daunorubicin...

JAZZ : 176.31 (+0.54%)
Zillow Group (ZG) to Report Q2 Earnings: Is a Beat in Store?

Zillow Group (ZG) to benefit from strong growth of it's Premier Agent Business. We expect the company to gain from increasing traffic at its mobile apps and websites, strong rental demand and MLS partnerships....

JAZZ : 176.31 (+0.54%)
PF : 66.20 (+0.18%)
PPL : 29.12 (+0.17%)
ZG : 47.39 (-0.06%)
ANSYS (ANSS) to Report Q2 Earnings: What's in the Offing?

Synergies from acquisitions are enabling ANSYS(ANSS) to bring innovative solutions to the market and also to enhance its foothold in the competitive simulations market.

ANSS : 171.60 (+0.33%)
JAZZ : 176.31 (+0.54%)
PPL : 29.12 (+0.17%)
ZG : 47.39 (-0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade JAZZ with:

Business Summary

Jazz Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. Company's goal is to build a broad portfolio of products through a combination of internal development and...

See More

Key Turning Points

2nd Resistance Point 179.61
1st Resistance Point 177.49
Last Price 176.31
1st Support Level 173.90
2nd Support Level 172.44

See More

52-Week High 184.00
Last Price 176.31
Fibonacci 61.8% 162.83
Fibonacci 50% 156.29
Fibonacci 38.2% 149.75
52-Week Low 128.58

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar